A Pivotal Phase II 90-day study of BTI-410 in Type 1 diabetes patients on immunosuppression therapy after kidney transplant surgery.
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Human proislet peptide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Boston Therapeutics
- 11 Apr 2018 New trial record
- 27 Mar 2018 According to a Boston Therapeutics media release, this trial is planned to initiate during the first half of 2018.